论文部分内容阅读
目的观察肿瘤标记物检测和核素骨显像对肺癌骨转移患者诊断的临床价值。方法肺癌骨转移患者102例,将其设为观察组,根据骨显像情况分为骨显像阳性组63例以及骨显像阴性组39例;同期选择健康体检人员107例,设为对照组;观察肿瘤标记物检测以及核素骨显像完成诊断后获得的效果。结果在癌胚抗原(CEA)、细胞角蛋白19的可溶性片段(CYFRA21-1)以及神经元特异性烯醇化酶(NSE)指标及阳性率方面,骨显像阳性组显著高于对照组以及骨显像阴性组(P<0.05)。结论肿瘤标记物检测联合核素骨显像的方法 ,能够获得更加明确的诊断,并对患者进行疾病分期,值得临床推广应用。
Objective To observe the clinical value of tumor marker detection and radionuclide bone imaging in diagnosis of patients with bone metastasis of lung cancer. Methods Totally 102 patients with bone metastasis of lung cancer were divided into observation group, 63 cases of bone imaging positive group and 39 cases of bone imaging negative group according to the bone imaging conditions. 107 healthy subjects were selected as the control group ; Observe the tumor marker detection and the results obtained after the completion of the diagnosis of radionuclide bone imaging. Results In the CEA, CYFRA21-1 and neuroendocrine enolase (NSE) markers and the positive rate, the bone imaging positive group was significantly higher than that of the control group and the bone Imaging negative group (P <0.05). Conclusion Tumor markers combined with radionuclide bone imaging methods can obtain a more definite diagnosis, and patients with disease staging, worthy of clinical promotion and application.